NCT03236974 - Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 5, 2017

Primary Completion Date

February 12, 2019

Study Completion Date

February 12, 2019

Conditions

Postmenopausal Women With ER+ HER2- Primary Breast Cancer

Interventions

DRUG

Standard Arm - Fulvestrant

500 mg Fulvestrant administered as two consecutive 5 ml intramuscular injections on Day 1, one in each buttock

DRUG

AZD9496

Administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy

Trial Locations (12)

Research Site, Schwerin

Research Site, Minden

Research Site, München

Research Site, Erlangen

Research Site, Derby

Research Site, Edinburgh

Research Site, London

Research Site, London

Research Site, London

Research Site, Manchester

Research Site, Poole

Research Site, Sutton in Ashfield